0 Days
0 Hours
0 Minutes
0 Seconds


BioHabana 2024 / “Science for a healthy life” The start is approaching!

BioHabana 2024 is the second edition of this scientific and business meeting. The innovation in Health requires the worldwide interconnection of innovation ecosystems.

The R&D&i activity becoming international and the globalization of the High Tech enterprises is a universal trend in the biotech, pharmaceutical and medical technology field. BioHabana 2024 will be a space for the construction of collaboration networks between science front-runners, key opinion leaders, entrepreneurs and businessmen.

There is an ongoing revolution of biological sciences in the XXI century, which has given rise to the concept of the “new biology”, as a science of convergence with Nanosciences and Data Science, which captures the complexity of biological systems.

It is necessary to extract the lessons that Covid-19 leaves us for future health emergency situations. Cuba's experience in controlling this disease indicates the epidemiological impact of social factors.  In the post-Covid19 stage, we will have an increase in the burden of mortality from chronic non-communicable diseases, among others, cancer and neurodegenerative diseases.

The concept of "One Health" teaches us the need for a holistic approach, which includes, in addition to human health, food production and environmental protection. A "clean" and "smart" industry (industry 4.0) is a necessity in the contemporary world.

The effective use of all these new possibilities will also require changes in the ways of managing value chains and in business models, which will have to be addressed with creativity and organizational innovation.

BioCubaFarma, the Cuban Biotechnological, Pharmaceutical and Medical Technology Industry Group, calls the scientific and business community of the world to the Congress BioHabana 2024. In this second edition we intend, together with scientists and businessmen, to continue the debate that we started in the previous edition and introduce new topics.

This Congress will be a unique space due to its scope and diversity, both in terms of subjects and actors, an innovation accelerator, and a tool for promoting cooperation and business.

Connectivity and globalization will characterize BioHabana 2024. We are looking forward to meet you in BioHabana 2024!


April 1 – 5, 2024


Melia Cohiba and Melia Habana hotels, Cuba

Web platform

BioHabana 2024 has a Web platform, which can be accessed through the link and through which the registration process must be carried out, submission of work summaries, access to event news and other elements.


BioHabana 2024 is preparing an attractive program based on scientific and business sessions. More than 120 relevant lecturers from different countries have confirmed their attendance. Besides, more than 1000 delegates are expected to attend the meeting.

Symposia with master lectures, workshops, posters and/or oral presentations will be organized in the following main topics:

  1. Cáncer
           Main subtopics:
            •   Tumor Biology: malignant transformation, tumor progression and metastasis
            •   New advances on cancer immunotherapy:
                    o   Inhibitors of check points
                    o   Adoptive cellular therapy
                    o   Cancer vaccines
                    o   Drug combinations and treatments
                    o   Resistance mechanism
            •   Biomarkers: Discovery and development
            •   Prevention, Diagnosis and early treatment
  2. Infectious and autoimmune diseases
           Main subtopics:
           •   COVID-19, impact on vaccine development. Current strategies. Lessons to face upcoming health emergencies
           •   Chronic infectious diseases. Therapeutic vaccines
           •   Acute infectious diseases
           •   Basic research, B and T cells, innate immunity, mucosal immunity, immune potentiation of the immune response and immunological memory
           •   Translational research:
                    o   Immunopathogenesis of Autoimmune Diseases
                    o   Animal models of autoimmune diseases
                    o   Diagnosis. Biological Therapies vs Conventional Treatments of autoimmune diseases
                    o   Applications of immunotherapy in autoimmune disorders
                    o   Induction of Immunological Tolerance
  3. Neurodegenerative diseases
           Main subtopics:
           •    Challenges and advances on the drug development for treating neurodegenerative diseases
           •    Neurosciences and Neurotechnologies. Approaches in the Industrial revolution 4.0
           •    Neuroinformatics and multiomics approaches for understanding brain diseases
           •    Neurotechnology and healthy aging
           •    Neurostimulation and neuromodulation
           •    Neurodevelopment and educational neurosciences 
           •    Cognitive neurosciences
           •    Hereditary ataxias
  4. Chronic inflammation and aging
           Main subtopics:
           •    Immune senescence and inflammation
           •    Cellular senescence
           •    Methods for estimating the biological age. Biological clocks.
           •    Strategies to reach a healthy aging/ “anti-aging” therapies 
           •    Panel about centenarians
  5. Bioprocesses. Development and design space
           Main subtopics:
          •    Fermentation and protein expression systems in mammalian cells, bacteria and yeast
          •    Protein purification
          •    Lyophilization, optimization, models
          •    Manufacturing of vaccines and biosimilars
          •    Design and processes for probiotics
          •    Space of design, quality by design
          •    Process Analytical technologies (PAT) and technologies for drug characterization
  6. Medical Technology and Industry 4.0
          Main subtopics:
          •    Processing of signals and biomedical images
          •    Sensors and medical instruments
          •    Nanosciences; Nanotechnologies and Nanomaterials
          •    Artificial Intelligence
          •    Telemedicine and home care
          •    Computerization in biomedical environment, Bioinformatics and computational biology
          •    Biomaterials and tissue engineering
          •    Modeling and simulation
          •    Biomechanics and bio-robotics 
          •    Rehabilitation technologies
          •    Medical physics and nuclear medicine
          •    Clinical engineering and management of health technologies
          •    Design of medical devices
  7. Agricultural biotechnology
          Main subtopics:
          •    Genetic improvement of plants for a more ecological agriculture
          •    Veterinary vaccines in the concept of one health 
          •    Industrial enzymes in improving nutrition
  8. Innovation in business models for high-tech sectors
           Main subtopics:
          •    License Agreements 
          •    Appraisal of Intangible Assets 
          •    Stock market 
          •    Businesses between Cuban and American companies for US market 
          •    Foreign investment businesses in Cuba   
          •    Successful business cases of Cuban biotechnology     
  9. Regulatory Science 
           Main subtopics:
          •    Health Authorizations
          •    Good manufacturing practices

          •    Implementation of Reliance Mechanisms and procedures

  10. IX International Workshop on Design and Conduct of Clinical Trials

          Main subtopics:
          •    Design and conduct of clinical trials
          •    Regulations, quality and transparency of clinical trials

  11. Microbiome Mini-symposium

Special sessions will be organized on:

  • Strategy and technologies for facing new pandemics
  • Collaboration Academy-Company. Innovation management 
  • Launching session of BioCubaFarma business portfolio, investment portfolio and products catalog 2024-2025
  • Trade Fair of the Biotechnological, Pharmaceutical and Medical Technology Industry
  • Spaces set up for bilateral meetings

There will be the possibility of virtual participation in the BioHabana 2024 Congress, with access to the summaries of all the works, a digital version of the posters, and online participation in the keynote conferences of the symposia.


Deadline for registration and submission of papers:

  • Extends up to: March 10, 2024

Those interested in sending the abstract of their contributions should do so through the event's official site in your user profile.      
The acceptance of the abstracts will be subject to the evaluation of the Scientific Committee. Non-approval does not invalidate you from participating as a Delegate.

BioHabana 2024 Abstract Template

Registration fee for international participants

  • Before the deadline: 300 euros
  • Late registration (after the deadline): 400 euros
  • Students: 100 euros
  • Companion: 100 euros 
  • Virtual participation (online): 150 euros
  • Pass to session: 80 Euros

For in person mode (with the exception of Companion and Pass to session categories), the fee payment for registration guarantees: 

  • Accreditation, materials of the event and access to all lectures and other forms of presentation, as well as the socio-cultural activities planned within the framework of BioHabana 2024.
  • Digital certification for the attendance mode 

Payment of the registration fee for the Companion category guarantees access to the opening and closing sessions of the event, as well as to all socio-cultural activities planned within the framework of BioHabana 2024.
Payment of the session pass fee guarantees access to all activities on the specific day of participation, as well as a digital certificate of participation.
Payment of the registration fee in the virtual mode guarantees:

  • Virtual access to all conferences.
  • Possibility of virtual presentation in short oral presentation or Poster format, if your work is approved by the Scientific Committee of the event.
  • Digital certificate accrediting the participation modality.

Data of bank account, in euros, for registration fee payment:

  • Bank account: No.0300000005803717  
  • Bank name: Banco Financiero Internacional 
  • Bank address: Calle 1ra y 0, Edificio Sierra Maestra, Playa, La Habana, Cuba
  • Reference: Congreso BioHabana 2024

There will also be a payment channel through the event's Web platform, for participants who prefer to use that route.

In all cases, you may download the: EVENT PAYMENT MODEL FOR INTERNATIONAL PARTICIPANTS file.
Once the model is completed and sent:, the corresponding invoice will be sent to you by email. 

Registration fee for national participants

  • Delegate: 5,000.00 CUP
  • Virtual participation (online): 2,000.00 CUP
  • Students: 500.00 CUP
  • Pass to session: 2,000.00 CUP

The payment of the registration fee guarantees in the in-person modality (except for the Pass to session):

  • Accreditation, event materials and access to all conferences and other forms of presentation, as well as to the socio-cultural activities planned within the framework of BioHabana 2024.
  • Digital certificate accrediting the participation modality.

Payment of the session pass fee guarantees access to all activities on the specific day of participation, as well as a digital certificate of participation.

Payment of the registration fee in the virtual mode guarantees:

  • Virtual access to all conferences.
  • Possibility of virtual presentation in short oral presentation or Poster format, if your work is approved by the Scientific Committee of the event.
  • Digital certificate accrediting the participation modality.

The bank account details to make the payment of the CUP registration fee are:

  • Bank account: 0300000006297715
  • Headline: EVENTO BIOHABANA 2024
  • Bank address: BFI 5TA Y 92, PLAYA, LA HABANA, CUBA
  • Reference: Congreso BioHabana 2024

In all cases, you may download the: EVENT PAYMENT FORM FOR NATIONAL PARTICIPANTS file. Once the model is completed and sent:, the corresponding invoice will be sent to you by email. 


Accommodation and transportation of foreign participants

It will be attended by the Havanatur Tourism Agency. Services include:

  • Accommodation per person-night with breakfast
  • Services of transportation from and to the airport, exclusive
  • Services of transportation from and to the Event venue
  • Havanatur service for personal assistance


Public prices per person per night expressed in USD.






Grand Muthu Habana










Memories Miramar





Starfish Montehabana










Meliá Habana






  • Havanatur assistance
  • Hotels in CP Plan (Accommodation + Breakfast)
  • Airport Entry and Exit Transfer.
  • Round trip transfer to the Event Headquarters


Trade Fair

Biotech, Pharmaceutical and Medical Technology Industry Trade Fair

We are pleased to inform you that in parallel to the BioHabana 2024 event, a trade fair will be held that will allow a close approach with BioCubaFarma companies, as well as with other related companies, both suppliers and customers.

At the fair, special sessions dedicated to the launch of prioritized company projects can be held, where new business opportunities can be shared with entrepreneurs from all over the world. 

On the other hand, a business round will be held, for which there will be a space for meetings that are previously coordinated by the parties based on the interests expressed through the event's Web platform, which will allow this possibility of coordination.


Sponsorship opportunities

Three categories of sponsorship will be established with their corresponding advertising fees: 

  • PLATINUM: Three categories of sponsorship will be established with their corresponding advertising fees: 
  • GOLD: Three categories of sponsorship will be established with their corresponding advertising fees: 
  • SILVER: contribution inferior to 5,000 Euros (for international sponsors) and less than 130,000 CUP (for national sponsors).

Highlights in this edition, for sponsors in the PLATINUM Category, the free offer of a 9 m2 space (stand) at the trade fair will be available to show their products and projects. Moreover, PLATINUM and GOLD categories, will have the opportunity to present a 20-minute conference about business opportunities of the company. Additionally, in the PLATINUM and GOLD categories, two delegates and one delegate will be exempt from paying the registration fee, respectively.

In all cases, the Event Payment Form for Sponsorship is filled out and downloaded from the following links, for INTERNACIONAL SPONSORS and NATIONAL SPONSORS, respectively. Once the model is completed and sent:, the corresponding invoice will be sent to you by email. 

Organizing Committee


  • Mayda Mauri Perez, PhD

Honorary President:

  • Eduardo Martínez Díaz, PhD


  • Rolando Pérez Rodríguez, PhD
  • Santiago Dueñas Carrera, PhD
  • David Curbelo Rodríguez, PhD
  • Isis B. Yera Alos, PhD
  • Lisset Hermida Cruz, PhD
  • Ricardo Silva Rodríguez, PhD
  • Ismary Nuñez Broño, MSc
  • Norkis Arteaga Morales, MSc
  • Tomás de la C. Hernández Regincos, MSc 
  • MSc. Raul de la Nuez Morales
  • Pablo Fonseca Rodríguez, MSc
  • Gisel Sanchez Rodríguez, MSc
  • Mildrey Monzón Martínez, MSc

Symposia and Special Sessions

  • Coordinators
    • Cancer

      Circe Mesa (CIM), Yanelys Morera (CIGB)
    • Infectious and autoimmune diseases

      Gerardo Guillén (CIGB), Dagmar García (IFV), Giselle Pentón (CIGB), Patricia Hernández (CIM)
    • Neurodegenerative diseases

      Roberto Rodríguez (CNEURO), Yanier Nuñez (CIDEM), Diana García (CIGB), Leslie Perez (CIM), Claudio Rodríguez. (BioCen)
    • Chronic inflammation and aging

      Agustín Lage (BCF), Ana Laura Añe Kouri (CIM)
    • Bioprocesses. Development and design space

      Alexis Labrada (Biocen), Katia Rashida (CIM), Oscar Cruz (CIGB), Yanely Herrera (IFV)
    • Medical Technology and Industry 4.0

      Arlem Lemes (COMBIOMED), Denis Rodríguez (COMBIOMED), Maria Carla Silvera (ETI)
    • Agricultural biotechnology

      Mario P. Estrada (CIGB), Lincidio Perez (CIGB), Alina Rodríguez (CIGB), Abel Hernández (CIGB)
    • Innovation in business models for high-tech sectors

      Norkis Arteaga (Oficina central)
    • Regulatory Science

      Olga Lidia Jacobo, Lisset Pérez
    • Collaboration Academy-Company. Innovation management

      Rolando Pérez (Oficina central), Isis Yera (Oficina central)
    • Covid-19 Learned Lections

      Gerardo Guillén (CIGB), Dagmar García (IFV)
    • Comunication

      Ismary Núñez Broño (Oficina Central)


PhD . Adriana Maria Rios Rincon

Dr. Rios Rincon earned a BSc (Occupational Therapy) at the Universidad Nacional de Colombia, and a MSc (Biomedical Sciences) at the Universidad de Los Andes, both in Bogotá, Colombia. She earned a PhD (Rehabilitation Science) degree at the University of Alberta, Edmonton, Canada. Her academic career began as an assistant professor at the Universidad del Rosario, School of Medicine and Health Sciences, Bogotá, Colombia, where she also served as the director of a MSc program in Rehabilitation Science for over a year. Currently, she is an assistant professor at the University of Alberta, Faculty of Rehabilitation Medicine, Department of Occupational Therapy. She is also an adjunct professor at the Faculty of Health at the University of Waterloo.

PhD . Alexander Kabanov

Mescal S. Ferguson Distinguished Professor and Director of the Center for Nanotechnology in Drug Delivery at the UNC Eshelman School of Pharmacy. He has conducted pioneering research in the nanomedicine field to treat cancers and diseases of the central nervous system.

PhD . Alexander Viktor Karaulov

Professor at the Clinical immunology and allergology, I.M. Sechenov First Moscow State Medical University. Alexander does research in Clinical Immunology and Allergology. Their current project is "Mucosal immunity" and " Molecular aspects of allergy"

PhD . Amy J. Karlsson

Associate Professor of Chemical and Biomolecular Engineering, Fischell Department of Bioengineering. University of Maryland. Her group uses protein engineering strategies to improve the understanding of human diseases and develop tools for drug design and disease diagnosis.

PhD . Andrea Alimonti

Head of the Molecular Oncology at the Institute of Oncology Research and full professor at the University of the Italian-Switzerland, at the University of Padova and at ETH Zurich. His approaches for developing state-of-the-art innovative treatments for cancer patients are based on the study of cancer initiation and senescence.

PhD . Andrei Gudkov

Professor of Oncology and Senior Vice President of Basic Science and the Garman Family Chair in Cell Stress Biology, Roswell Park Cancer Institute. His areas of expertise are cancer genetics, new cancer therapies, drug discovery, aging and effects of radiation

PhD . Anish Suri

President/Chief Scientific Officer, Cue BioPharma Inc. He is an immunologist with extensive experience in basic and translational research focused on immuno-oncology, autoimmune disorders, transplantation rejection, and inflammation.

PhD . Antonio Miguel Cruz

BSc degree in Nuclear Engineering, MSc in Bioengineering, Ph.D. degree in Bioengineering. Antonio Miguel Cruz is a distinguished academic with a wealth of experience and expertise in the field of digital technologies for healthy ageing. As an Associate Professor in the Department of Occupational Therapy within the Faculty of Rehabilitation Medicine at the University of Alberta, he plays a pivotal role in shaping the future of healthcare and rehabilitation. Additionally, Dr. Miguel Cruz serves as an affiliate researcher at the Glenrose Rehabilitation Research, Innovation & Technology, where he actively contributes to groundbreaking research initiatives. His commitment to advancing the field extends further as an Adjunct Associate Professor in the Faculty of Health at the University of Waterloo.

PhD . Anupam Bishayee

Professor of Pharmacology at the Lake Erie College of Osteopathic Medicine. His laboratory is investigating cancer preventive and therapeutic effects of natural products, medicinal plants, phytochemicals, dietary and synthetic agents and the associated anti-inflammatory and cell signal-modulatory effects.

PhD . Arnold J. Levine

Professor Emeritus of Systems Biology at the Institute for Advanced Study in Princeton, New Jersey. A widely acclaimed leader in cancer research who discovered the p53 tumor suppressor protein.

PhD . Calogero Caruso

Formerly Full Professor of General Pathology, is Professor Emeritus at the University of Palermo, Italy. ACADEMIC EDUCATION: He graduated from the School of Medicine, University of Palermo, in 1971 (magna cum laude). RESEARCH ACTIVITIES & PUBLICATIONS: He was founder and editor-in-chief of the journal Immunity & Ageing (2004-2018), and has authored 388 publications (13,710 citations), mostly on ageing, age-related diseases and longevity, indexed on Scopus (H index of 61). He has recently edited the book “Centenarians. An example of positive biology.” for Springer Nature and, with Prof. Giuseppina Candore, the book “Human Aging. From Cellular Mechanisms to Therapeutic Strategies”. NETWORKING: He was national coordinator of Italian Ministerial Project on Centenarians and Longevity (2017-2020). He was Coordinator of the PhD program in Molecular Medicine and Biotechnology (formerly Pathobiology) (1998-2018). The national and international recognition of his scientific achievements in the field of Biogerontology is documented by funded projects, by the number of citations of his papers, by invitations to national and international congresses and meetings, by his activity as a project reviewer and by organization of international conferences.

PhD . Carlos A. Guzmán

Prof. Carlos A. Guzmán (MD, PhD) is head of the department Vaccinology and Applied Microbiology at the Helmholtz Centre for Infection Research (HZI) and also APL professor at the Hannover Medical School.
He studied Medicine at the National University of Rosario and received his specialization in Medical Bacteriology in Argentina. He acquired his doctorate in Medicine and Surgery, becoming also a doctor in Microbiological Sciences at the University of Genoa.
In 1994, he became head of the Vaccine Research group at the HZI. He has been active in the field of Vaccinology since 1989. His work led to the discovery of new adjuvants, the establishment of Salmonella spp. as a delivery system for DNA vaccines and therapeutic molecules, and the development of vaccine candidates against different infectious diseases. He has published over 260 papers in international journals and is co-inventor of numerous international patents.
Prof. Guzmán is member of the editorial boards of Bioengineered, Frontiers Microbial Immunology, Frontiers in Mucosal Immunology, Frontiers in Vaccines and Molecular Therapeutics, Vaccine, and Vaccines.

PhD . Daniel San Juan Orta

He is an International expert in Neurology, Clinical Neurophysiology and Epileptology. Dr. Daniel San Juan Orta is currently president of the Mexican Chapter of the ILAE (International League Against Epilepsy), CAMELICE (Mexican League Against Epilepsy). He has more than twelve years of experience coordinating Clinical Research about Epilepsy. More than 8 years of experience as principal investigator in pharmaceutical sector. Active member of several national and international neuro-societies and past-president of the Mexican Clinical Neurophysiology society and Active member of the National Medical Society of Mexico. Neuro-scientist with more than 70 journal publications related to the field of neurosciences.

PhD . Daniela Frasca

Research Associate Professor in Microbiology and Immunology University of Miami Miller School of Medicine.
PhD in Cell Biology and Developmentfrom the University of Rome.
Research interests: B cell immunosenescence, obesity and immune aging.

PhD . Djordje Miljkovic

PhD. Profesor de Investigación. IBISS, Jefe del Departamento de Inmunología. Universidad de Belgrado. Serbia. Intereses de investigación: Neuroinmunología. Interacción SNC-sistema inmunológico-microbiota. Células dendríticas tolerogénicas en el tratamiento de la autoinmunidad. Modulación fisiológica y farmacológica de la autoinmunidad. Experiencia en encefalomielitis autoinmune experimental, diabetes tipo 1 e inmunología celular. Publicaciones: 103 artículos revisados por pares en revistas científicas multidisciplinarias internacionales revisadas por pares, hasta el momento. 1er autor en 20 publicaciones, último autor en 22 y autor correspondiente en 9 publicaciones adicionales. Citas – 2458, índice h – 25, índice i10 – 49. IF total 379,394, IF promedio 3,683.

PhD . Franco Cavali

Head of Oncology at Bellinzona Hospital and Professor at the Universities of Bern and Varese. He is a researcher at the Southern Swiss Institute of Oncology. He is interested in the fate of cancer patients in the Third World and stigmatizes the weight of the American pharmaceutical industry.

PhD . Graham Pawelec

University of Tübingen, Germany. Master's degree in Natural Sciences and PhD in Transplant Immunology. Professor of Experimental Immunology. Co-Editor-in-Chief of "Immunity & Ageing" and was Co-EiC of “Cancer Immunology Immunotherapy”. Research interests: Immunosenescence, cancer immunotherapy, immune monitoring, vaccination, and immune ageing in humans.

PhD . Kâmil Uludağ

Kâmil Uludağ is Full Professor at the Department of Medical Biophysics, University of Toronto. He completed his Ph.D. in Physics in 2003 on Near-Infrared Optical Spectroscopy (Humboldt University, Berlin) and moved for a postdoc position to the Center for Functional MRI (UCSD, San Diego, USA) to work on the physiological and physical basis of functional MRI.
His main research focus includes: Physical and physiological foundations of functional MRI, Clinical application of quantitative MRI at 3 and 7 Tesla, Anatomical MRI in post mortem and in vivo brain tissue and Artificial intelligence in fundamental Neuroscience and Diseases.

PhD . Kelvin Lee

Director of the Indiana University Simon Comprehensive Cancer Center. Senior Associate Dean of Cancer Research at IU School of Medicine and the H.H. Gregg Professor of Oncology. He specializes in Hematology for Multi-D Oncology Clinic and his primary location is Multi-D Oncology Clinic, Indianapolis, Indiana

PhD . Lili Liu

Lili Liu earned her BSc in Occupational Therapy, and her MSc and PhD in Rehabilitation Science, at McGill University. She is currently a professor in the School of Public Health Sciences, and dean of the Faculty of Health at the University of Waterloo. Liu’s research program examines acceptance and adoption of technology innovations by older adults, their care partners, health care professionals, and unlicensed care personnel. Her team focuses on approaches to inform and implement policies that create safe environments for older adults living with dementia at risk of going missing.

PhD . Liubov Shynkarenko Sichel

Leading Ukrainian microbiologist, founder of Biotechnological education in Ukraine, Dean Emeritus of the Faculty of Biotechnology and Biotechnic in National Technical University “Kyiv Polytechnical Institute” in Kyiv, Ukraine and co-founder, chief scientific officer (CSO) and chief executive officer (CEO) of Stellar Biotic. Her approaches for developing state-of-the-art of microbiome are related to conduct advanced research of probiotic strains of lactic acid bacteria, their metabolites and structural composition for developing advanced microbial and biotherapeutic formulations for human and animal use.

PhD . Luis Ariel Diago Márquez

Luis Diago graduated from the Polytechnic University of Havana, Cuba (CUJAE) in 1995 as engineer in telecommunications, and worked as a professor there for 11 years. He received his M.S. in Applied Informatics in 1997 and Ph.D in Bioengineering in 2006 from CUJAE. After working in a New Energy and Industrial Technology Development Organization (NEDO) project at Tokyo Institute of Technology, Japan (TiTech) in 2003, he received also a Ph.D from TiTech in 2008 and worked as a JSPS Postdoctoral Fellow there until 2010. He has been a researcher at Interlocus (a spin-off of TiTech) since 2010 and Meiji Institute for Advanced Mathematical Sciences (MIMS) since 2013, working on the application of image processing and machine learning to origami engineering and autonomous driving.

MSc . Luis R. Barriere Avalos

Biomedical engineer. Postgraduate degrees in: Renewable Energy Management, Clinical Engineering and Electro-medicine. With 23 years of experience as a teacher-researcher in areas of Engineering at the following universities: U. Don Bosco (UDB), U. Centroamericana José Simeón Cañas (UCA), U. Evangélica de El Salvador (UEES) and U. Dr. Andrés Bello (UNAB), all in El Salvador. Biomedical Specialist Consultant to the World Bank. Accidental Biomedical Expert of the Attorney General's Office of the Republic, in the Prosecutor's Unit for Crimes Relating to Life and Physical Integrity. Facilitator Certified by the Salvadoran Institute of Professional Training_ INSAFORP for Biomedical topics.

PhD . Luisa Lilia Rocha Arrieta

Prof. Rocha is SIN-III Researcher and 3E-Full Professor, Department of Pharmacology, Centro de Investigación y de Estudios Avanzados (CINVESTAV).
She is a Full Member of the Latin American Brain Initiative (LATBrain). Member of the Joint ILAE-AES Task Force on Translational Research. She is the author of more than 120 scientific articles in indexed journals, 36 book chapters and 4 books.
She has made notable contributions to the molecular pathogenesis of epilepsy.

PhD . Mamun Al Mahtab

MSc in Gastroenterology, University of London, UK, 1998; Specialist in Hepatology, Bangabandhu Sheikh Mujib Medical University, Bangladesh, 2006 and PhD in Medicine, University of Malaya, Malaysia, 2022; Head of the Interventional Hepatology Division at Bangabandhu Sheikh Mujib Medical University (BSMMU) and former Chairman of the Department of Hepatology. Professor Mahtab has more than 350 publications in peer-reviewed scientific journals and 550 scientific conference presentations.

PhD . Marina Mokronosova

Works and runs the allergology department of the prestigious I.I. Mechnikov. Her field of scientific and practical interests for 40 years includes the study of atopic dermatitis, allergic rhinitis, bronchial asthma, food and drug allergies, and molecular allergology. She is a regular lecturer at the International School of Molecular Allergology "INUNIMAI" and the general director of the Russian allergological center "Ado".

PhD . Markus Frank

Associate Professor of Pediatrics and of Dermatology at Harvard Medical School, Associate Physician of Medicine at Brigham and Women's Hospital, a member of the Stem Cell Program at Boston Children's Hospital. His work focuses in the study of normal tissue-specific and malignant cancer stem cells.

PhD . Martha Carlin

Visionary leader and the CEO and Founder of The BioCollective, a company dedicated to advancing microbiome research. She discovered a significant connection between chronic diseases and the gut microbiome, and her company's mission is to provide valuable tools and information for researchers studying the gut microbiome's role in chronic diseases and to develop probiotic systems to restore health. Her team has developed innovative methods for collecting and analyzing microbiome samples, contributing significantly to understanding gut health's impact on overall wellness.

PhD . Mary Reid

Chief of Cancer Screening, Survivorship and Mentorship at Roswell Park Comprehensive Cancer Center. She is a Distinguished Professor of Oncology in the Department of Medicine. Her work is focused in Lung Cancer Screening and other cancer screening initiatives.

PhD . Ming Chen

Profesor at Zhejiang University, College of Life Sciences, Department of Bioinformatics. His work aims at the research and development Bioinformatics for applications in dataset from plant science and biomedical experiments.

PhD . Natasha Frank

Associate Professor, Medicine, Harvard Medical School. Associate Physician, Medicine, Brigham and Women's Hospital, Interim Clinical Chief, Genetics, Brigham and Women's Hospital. Her work is focused on the relationship of multipotent stem cells to genetic diseases and cancer.

PhD . Nur A. Hasan

Molecular Microbiologist specialized in genomic, microbiome R&D and strategic development of technology innovation in the biotech and life science industries. Currently Dr Hasan directs the strategic leadership and scientific functions of EzBiome Inc. This microbiome company applies precision taxonomy to achieve definitive microbial identification and expedite the discovery and development of microbiota-based therapeutics and companion diagnostics for microbiome related disease.

PhD . Olukemi K. Amodu

Professor of Genetics/Molecular Biology and Public Health at the Institute of Child Health, University of Ibadan, NIGERIA. Expertise: Molecular Parasitology Immunology of Infectious Diseases,PCR, Plasmodium Molecular Epidemiology, Molecular Biology, Falciparum Malaria, Human Genetics Immunology Malaria Host-Pathogen Interactions, Next Generation Sequencing. She obtained Master’s and PhD (in Molecular Biology/Genetics) from the University of Ibadan. After her postdoctoral training at the Harvard University, USA, she has focused on studies in genetic diversity of human and parasite genes studies, investigating markers of virulence and of susceptibility in the Nigerian population, which have resulted in landmark findings.

PhD . Pamela Maher

Research Professor. Cellular Neurobiology Laboratory. San Diego, CA USA. Maher screens for compounds that could slow or stop the progression of neurodegenerative diseases, with a focus on Alzheimer’s. Her novel approach uses compounds derived from natural products, such as strawberries, turmeric and cannabis, in order to treat the cellular aging and memory loss observed in Alzheimer’s.. Maher and her team have taken multiple drug candidates from conception in the laboratory into clinic trials. Currently, two compounds, CMS121 and J147, are undergoing clinical trials for the treatment of Alzheimer’s. In mice, these compounds were found to protect neurons and prevent the molecular changes that are associated with aging.

PhD . Peter Fedichev

CEO of GERO, the leading bioinformatic/AI company in the field of antiaging research. With a background in physics, he is in the field of Geroscience. Also interest in the influence of aging in tumor development and progression.


BSc degree in Electrical Engineering. MSc in Electrical Engineering. Ph.D. in Electrical Engineering.
Ratko Magjarević received his Ph.D. in Electrical Engineering in 1994 from the University of Zagreb, Faculty of Electrical Engineering. After his appointment in industry at the Institute of Electrical Engineering “Koncar,“ he joined the Electronic Measurement and Biomedical Engineering Group at the University of Zagreb Faculty of Electrical Engineering and Computing. He is full professor teaching several courses in Electronic Instrumentation and Biomedical Engineering at undergraduate, graduate and at postgraduate studies.

PhD . Raúl de Jesús Cano Chauvell

Chairman, EDC BioSynergy, LLC, San Luis Obispo, CA ,Chief Executive Officer, Ancient Organics Bioscience, Inc. Chief Scientific Officer, The BioCollective, Denver, Professor Emeritus, California Polytechnic State University, San Luis Obispo, CA, Visiting Professor, University of Puerto Rico, Rio Piedras, Puerto Rico. His approaches for developing state-of-the-art of microbiome are in three principal areas: Rationally Designed Probiotic Products, Regulatory Compliance and Product Safety; and Microbiome Analysis and Product Development Support.

PhD . Roberto Lent

Professor of Neuroscience, Federal University of Rio de Janeiro
Director of the Brazilian Science for Education Network
Director of the Unesco Chair of Sci4Ed,
One of the Directors of the Brazilian Academy of Sciences.
He has made notable contributions to the quantification of cell populations of the human brain.
He is the author of more than 150 scientific articles in indexed journals. He is the main author of the neuroscience textbook "One Hundred Billion Neurons", and of the children's book collection "The Adventures of a Remembering Neuron".

PhD . Santiago Gonzalez

Professor of Oncology and Senior Vice President of Basic Science and the Garman Family Chair in Cell Stress Biology, Roswell Park Cancer Institute. His areas of expertise are cancer genetics, new cancer therapies, drug discovery, aging and effects of radiation

PhD . Sheikh Mohammad Fazle Akbar

MD. PhD, Senior Researcher, Hepatology and Metabology Department, Ehime University, Matsuyama, Japan. Dr. Akbar has authored more than 200 articles in international peer-reviewed journals. He is also actively involved in developing medical science by participating in the publication of medical journals. He has compiled several chapters and books about Hepatology and Gastroenterology. He is a regular reviewer of several scientific journals and editor of multiple scientific journals.

PhD . Steffen Leonhardt

Steffen Leonhardt was born in Frankfurt, Germany, on Nov. 6th, 1961. He holds a M.S. in Computer Engineering from SUNY at Buffalo, NY, USA, a Dipl.-Ing. and a Dr.-Ing. degree in Control Engineering from Technical University of Darmstadt, Germany, and a Dr. med. degree from the Medical School of Goethe University, Frankfurt, Germany. He has 5 years of R&D management experience in medical engineering industry and was appointed Head of the Philips Chair of Medical Information Technology at RWTH Aachen University, Aachen, Germany, in 2003. His research interests include physiological measurement techniques, personal health care systems and feedback control systems in medicine.

PhD . Stephen Connelly

Steve is a co-founder, Director and Chief Scientific Officer of Equillium where he oversees the discovery and development of several novel therapeutics for the treatment of autoimmune and inflammatory diseases. Prior to co-founding Equillium, Steve was an investment Principal at BioMed Ventures, a life sciences venture capital group, where he helped manage a venture portfolio of therapeutic, device and diagnostic companies. Steve joined Biomed Ventures from aTyr where he served as Director of Business Development and Therapeutic Alliances and assisted in raising over $150M through private and public financings. Prior to aTyr, he was a Senior Scientist at The Scripps Research Institute, where he worked on multiple drug discovery projects spanning different therapeutic areas, including development work with tafamidis (Vyndaqel®), a first-in-class drug approved for the treatment of familial amyloid neuropathy, and a second-generation inhibitor, acoramidis, recently approved for treatment of familial amyloid cardiomyopathy.

PhD . Tamás Fülöp

University of Sherbrooke, Quebeq, Canada. Medical Doctor and PhD in in Biochemistry and Immunology. Director of the Age Research Centre and Full Professor within the Faculty of Medicine and Health Sciences at the University of Sherbrooke. Head of the Immune Inflammation Laboratory and Medical Director of the Memory Clinic. Editor-in-Chief of Gerontology and Interdisciplinary topics in Gerontology and Geriatrics. Research interests: Immunosenescence, inflammation, immune aging and its association with age-related diseases.

PhD . Thomas Rothstein

Professor and Founding Chair of the Department of Investigative Medicine and Director of the Center for Immunobiology at the Western Michigan University, Homer Stryker MD School of Medicine. His work is focused on B lymphocytes and the antibodies they produce with particular interest in the subpopulation termed B1 cells




Actualizan información sobre BioHabana 2024

14 February, 2024

....El Comité Organizador (CO) del Congreso Internacional BioHabana 2024 informa el aplazamiento de la fecha límite para la inscripción y entrega de los trabajos hasta el 10 de marzo próximo. Los interesados en participar con sus contribuciones deberán enviar los resúmenes a través del sitio…